Understanding Late-Stage Clinical Trial Failure in Multiple Sclerosis: Insights from ClinicalTrials.gov

Area of Science:

• Neurology
• Clinical Trials
• Pharmaceutical Research

Background:

• Clinical trial failures, unrelated to safety or efficacy, waste resources and pose risks.
• Multiple sclerosis (MS) drug trials are a significant area of clinical research.
• Understanding failure rates in MS trials is crucial for optimizing drug development.

Purpose of the Study:

• To analyze the failure rates of late-stage multiple sclerosis clinical trials.
• To identify factors associated with clinical trial failure in MS.
• To provide insights for improving the success rate of MS clinical trials.

Main Methods:

• Searched ClinicalTrials.gov for Phase III and IV MS drug trials (2008-2024).
• Classified trials as normally ended or failed based on recruitment and reported reasons.
• Utilized Kaplan-Meier and logistic regression analyses to assess time to trial end and identify failure predictors.

Main Results:

• 25.2% of 282 analyzed MS clinical trials failed, with failed trials ending ~10 months earlier.
• Primary failure reasons included low recruitment (28.2%) and business decisions (26.8%).
• Trials focused on drug safety and those with ≥50 centers showed lower failure risk.

Conclusions:

• Approximately one in four late-stage multiple sclerosis clinical trials do not succeed.
• Strategies to enhance patient recruitment and expand the number of study sites are recommended.
• Addressing recruitment challenges and logistical issues can improve MS trial outcomes.